This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Print Page   |   Contact Us   |   Sign In   |   Register
Community Search
HOS 2019: Scientific Program
Share |

To view the preliminary scientific program, click here


Session Information

Monday, April 8, 2019

Keynote I Session

HOS: The Journey from Characterisation to QC
Carl Jone, Braine l'Alleud, Brussels


Discovery and Candidate Selection Session

A Rational Preformulation Approach for Biologics Aiding Candidate Selection at the Preclinical Stage
Pradyot Nandi, Bristol-Myers Squibb Company, Princeton, NJ USA

Darren Bates, Amgen Inc., Thousand Oaks, CA USA

HOS in Development Session

Antibody Higher Order Structure Analysis using High Throughput Protein Conformational Array for Product and Process Understanding
Dennis Yu, Bristol-Myers Squibb Company, Devens, MA USA

On the Diversity and Polymorphic Nature of Protein Aggregates
Vito Foderà, University of Copenhagen, Copenhagen, Denmark

Applications of 2D NMR in Product Development: Bridging the Gap Between Product Quality Attributes and HOS of mAbs
Arun Alphonse IgnatiusPfizer, Inc., Chesterfield, MO USA


Biological Consequences of HOS Session

Relationship Between Physicochemical and Biological Properties with Higher Order Structure of Monoclonal Antibodies
Haripada Maity, Bioverativ, a Sanofi company, Waltham, MA USA

Characterization of the Structural Determinants Governing Immunogenic Response to Multi-domain Biotherapeutics
Malgorzata Gonciarz, Eli Lilly and Company, Indianapolis, IN USA


Tuesday, April 9, 2019

Keynote II Session

Analysis, Control and Engineering of Protein Dynamics, Stability and Aggregation
Paul Dalby, University College London, London, United Kingdom


Established Methods and Fundamentals for HOS Session 

Kinetic Analysis of the Conformational Stability and Aggregation of mAbs Using Calorimetry
Ernesto Freire, Johns Hopkins University, Baltimore, MD USA

Characterization and Biological Relevance of Protein Aggregates and Other Particles 100-20000nm in Size (Submicron and Subvisible)
Linda Narhi, Amgen Inc., Thousand Oaks, CA USA

Computational Approaches to Predict Developability of Biotherapeutics: An Overview
Saeed Izadi, Genentech
, a Member of the Roche Group, South San Francisco, CA USA


Emerging Technology for HOS Evaluation Session

Bioinformatics Methods for Comparison of NMR Spectra
Bostjan Japelj, Lek, a Sandoz company, Ljubljana, Slovenia

Joshua Sharp, University of Mississippi, Oxford, MS USA

Advancing Cryo-EM in Drug Discovery
Claudio Ciferri, Genentech, a Member of the Roche Group, South San Francisco, CA USA


Young Scientist Session

Speaker information coming soon! 


HOS Biosimilarity and Comparability Session Session

John Hickey, University of Kansas, Lawrence, KS USA

Chemical Structure and Composition of Major Glycans Covalently Linked to Therapeutic Monoclonal Antibodies by Middle-Down Nuclear Magnetic Resonance
David Keire, CDER, FDA, Silver Spring, MD USA

Gi Hyun Kim, Ministry of Food and Drug Safety (MFDS), Cheongju-si, Korea

Omar Tounekti, Health Canada, Ottawa, ON Canada


Wednesday, April 10, 2019

Molecular Framework beyond mAbs Session

Higher Order Structure Characterization of Bispecific Antibodies: the Platform and the Variants
Hui-Min Zhang, Genentech, a Member of the Roche Group. South San Francisco, CA USA


Late Breaking Session

Speaker information coming soon! 


more Calendar

2/12/2019 » 3/1/2019
WCBP 2019 On-Demand Stream

3/12/2019 » 3/13/2019
CMC Strategy Forum Latin America 2019

3/12/2019 » 3/15/2019
AT Europe 2019

Featured Members
William Weiss, Eli Lilly and CompanyFind out more about Will in this month's Member Spotlight!

Membership Software Powered by YourMembership  ::  Legal